The stroke-related sarcopenia
Conditions
Interventions
Experimental group:Propranolol 10 mg tid was given orally for 3 days
Control group:Vitamin C tablets 100 mg tid were given orally for 3 days
Sponsors
The Third Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-80, male or female; 2. Within 1-7 days of onset; 3. According to The Chinese Guidelines for the Diagnosis and Treatment of Acute ischemic Stroke 2018, meet the diagnosis of acute ischemic stroke, or according to the Chinese Guidelines for the Diagnosis and Treatment of Cerebral Hemorrhage 2019, meet the diagnosis of hemorrhagic stroke, and have a first attack or previous attack but good recovery (no functional disorder); 4. NIHSS score of 6-25, including patients with thrombolytic thrombolysis or surgical failure; 5. Previous or no history of taking antihypertensive drugs or propranolol (note: patients who have taken antihypertensive drugs or propranolol for a long time in the past can be included in this study); 6. Informed consent of patients and their families; 7. COVID-19 nucleic acid screening is negative.
Exclusion criteria
Exclusion criteria: 1. Stroke of special etiology (such as central nervous system vasculitis, mei toxic cerebrovascular inflammation, coagulopathy, etc.), and stroke with recurrence within 3 months; 2. Cerebral hernia and persistent epilepsy; 3. In critical condition: unstable vital signs (respiration, blood pressure, blood oxygen, heart rate, etc.) and/or MODS; 4. Complicated with severe infection, infectious disease, myocardial infarction (within 3 months), chronic renal insufficiency, abnormal liver function (ALT > 2 times normal upper limit or AST > 2 times normal upper limit), autoimmune diseases, and other visceral dysfunction; 5. The presence of one or more of the following contraindications to propranolol: heart rate < 56 beats/min; systolic blood pressure <100 mgHg; second or third degree atrioventricular block; heart failure; a history of asthma and severe dyspnea; 6. The presence of other neurological diseases, dementia or mental disorders affecting compliance and assessment before onset; 7. Tumor patients; 8. Abnormal blood system: HGB < 90 g/L, WBC < 4.0×10^9/L, PLT < 100×10^9/L; or coagulation disorders; 9. Allergic constitution; 10. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Mass of Muscle; | — |
Countries
China
Contacts
Public ContactHuimin Yi
The Third Affiliated Hospital of Sun Yat-sen University
Outcome results
None listed